Nidan Labs FY26 net profit falls 24% to ₹150.60 lakh
Nidan Labs reported a 24% decline in FY26 net profit to ₹150.60 lakh despite a rise in revenue to ₹2,554.16 lakh. The Board re-appointed two independent directors and the statutory auditor for five-year terms.
*this image is generated using AI for illustrative purposes only.
Nidan Labs & Healthcare reported a 24% decline in net profit to ₹150.60 lakh for the financial year ended March 31, 2026, compared to ₹197.69 lakh in the previous year. Revenue from operations increased to ₹2,554.16 lakh from ₹2,452.75 lakh in FY25. The Board approved the audited financial results during its meeting on May 25, 2026, alongside the re-appointment of key personnel and auditors.
Financial Performance
Total income for FY26 stood at ₹2,739.73 lakh, a marginal increase from ₹2,677.81 lakh in the prior year. The company reported an exceptional item of ₹40.00 lakh during the year. Profit before tax for the year was ₹244.38 lakh, lower than the ₹276.02 lakh recorded in FY25. Basic earnings per share (EPS) decreased to ₹1.08 from ₹1.42 in the corresponding previous period.
| Particulars | Year Ended 31-Mar-26 (₹ in lakhs) | Year Ended 31-Mar-25 (₹ in lakhs) |
|---|---|---|
| Revenue from Operations | 2,554.16 | 2,452.75 |
| Total Income | 2,739.73 | 2,677.81 |
| Total Expenses | 2,455.35 | 2,401.79 |
| Net Profit for the year | 150.60 | 197.69 |
| Basic EPS | 1.08 | 1.42 |
Governance Approvals
The Board approved the re-appointment of Mr. Nilesh Bide and Mr. Abhinay Nerurkar as Non-Executive Independent Directors for their second terms. Both appointments are effective from August 20, 2026, for a period of five years, subject to shareholder approval. Additionally, M/s R. K. Chapawat & Co., Chartered Accountants, was re-appointed as the statutory auditor for a further period of five years up to the 31st Annual General Meeting.
Auditor Declaration
The statutory auditors, M/s R. K. Chapawat & Co., issued an unmodified opinion on the financial results for FY26. The disclosures were made in compliance with Regulation 30 of the SEBI (LODR) Regulations. The company confirmed that neither of the re-appointed directors is debarred from holding the position of director by SEBI or any other authority.
Historical Stock Returns for Nidan Labs & Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | +5.43% | -6.73% | -23.42% | -32.95% | -87.64% |
What specific factors drove the increase in expenses that led to the 24% decline in net profit despite revenue growth?
How does the company plan to restore earnings per share growth given the drop from ₹1.42 to ₹1.08?
What strategic initiatives are in place to improve profit margins in the upcoming financial year?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
